PaxMedica (PXMD) Stock Price, News & Analysis $0.69 -0.07 (-9.16%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$0.68▼$0.7650-Day Range$0.69▼$5.5352-Week Range$0.68▼$69.19Volume484,265 shsAverage Volume3.64 million shsMarket Capitalization$1.59 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media PaxMedica MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside332.3% Upside$3.00 Price TargetShort InterestBearish14.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 10 Articles This WeekInsider TradingSelling Shares$6,570 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($9.35) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPaxMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, PaxMedica has a forecasted upside of 332.3% from its current price of $0.69.Amount of Analyst CoveragePaxMedica has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.30% of the outstanding shares of PaxMedica have been sold short.Short Interest Ratio / Days to CoverPaxMedica has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PaxMedica has recently increased by 651.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPaxMedica does not currently pay a dividend.Dividend GrowthPaxMedica does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PXMD. Previous Next 3.1 News and Social Media Coverage News SentimentPaxMedica has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for PaxMedica this week, compared to 1 article on an average week.Search InterestOnly 11 people have searched for PXMD on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.MarketBeat Follows1 people have added PaxMedica to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PaxMedica insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,570.00 in company stock.Percentage Held by Insiders57.90% of the stock of PaxMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.28% of the stock of PaxMedica is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PaxMedica are expected to grow in the coming year, from ($9.35) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PaxMedica is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PaxMedica is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPaxMedica has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About PaxMedica Stock (NASDAQ:PXMD)PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.Read More PXMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PXMD Stock News HeadlinesDecember 8, 2023 | finance.yahoo.comPaxMedica CEO Featured in Just-Released Fireside Chat VideoDecember 7, 2023 | americanbankingnews.comFY2023 Earnings Estimate for PaxMedica, Inc. (NASDAQ:PXMD) Issued By HC WainwrightDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 6, 2023 | finance.yahoo.comPaxMedica Releases Fireside Chat Video with CEO Howard WeismanDecember 5, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of PaxMedica (PXMD) with Buy RecommendationDecember 5, 2023 | americanbankingnews.comPaxMedica (NASDAQ:PXMD) Now Covered by HC WainwrightDecember 4, 2023 | benzinga.comPaxMedica Stock (NASDAQ:PXMD), Analyst Ratings, Price Targets, PredictionsDecember 1, 2023 | finance.yahoo.comPaxMedica Closes on Public Offering Reaching Estimated $7MDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 25, 2023 | finance.yahoo.comPaxMedica Announces Closing of $7.0 Million Public OfferingNovember 22, 2023 | finanznachrichten.dePaxMedica, Inc.: PaxMedica Announces Closing of $7.0 Million Public OfferingNovember 22, 2023 | finance.yahoo.comPaxMedica Announces Pricing of $7M Public OfferingNovember 22, 2023 | investorplace.comWhy Is PaxMedica (PXMD) Stock Up 57% Today?November 21, 2023 | finance.yahoo.comPaxMedica News of FDA Type-B Meeting Shared in Audio BroadcastNovember 20, 2023 | investorplace.comWhy Is PaxMedica (PXMD) Stock Down 40% Today?November 20, 2023 | finanznachrichten.dePaxMedica, Inc.: PaxMedica Announces Pricing of $7.0 Million Public OfferingNovember 20, 2023 | markets.businessinsider.comCrude Oil Gains Over 2%; PaxMedica Shares PlungeNovember 20, 2023 | msn.comWhy PaxMedica Stock (PXMD) Is Down Nearly 40% TodayNovember 20, 2023 | finance.yahoo.comPaxMedica Announces Pricing of $7.0 Million Public OfferingNovember 18, 2023 | ca.finance.yahoo.comPaxMedica, Inc. (PXMD) Stock Price, News, Quote & History - Yahoo FinanceNovember 17, 2023 | finance.yahoo.comPaxMedica Releases Q3 2023 Financial Report, Corporate UpdateNovember 17, 2023 | finance.yahoo.comPaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial DataNovember 15, 2023 | finance.yahoo.comPaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business UpdateNovember 14, 2023 | msn.comWhat's Going On With PaxMedica Stock Today?November 10, 2023 | finance.yahoo.comPaxMedica CMO Featured in Latest Bell2Bell Podcast ReleaseNovember 9, 2023 | finance.yahoo.comPaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell PodcastNovember 9, 2023 | finance.yahoo.comPaxMedica Phase 2 Study Results Published in Peer-Reviewed JournalSee More Headlines Receive PXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PaxMedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PXMD CUSIPN/A CIK1811623 Webwww.paxmedica.com Phone914-987-2876FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+332.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($24.4176) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,610.14% Return on Assets-458.85% Debt Debt-to-Equity Ratio0.02 Current Ratio0.99 Quick Ratio0.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book4.63Miscellaneous Outstanding Shares2,290,000Free Float965,000Market Cap$1.59 million OptionableNot Optionable Beta0.28 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Howard J. Weisman (Age 64)CEO & Chairman Comp: $640kMr. Stephen Douglas Sheldon (Age 43)CFO & COO Comp: $198.66kDr. David W. Hough M.D. (Age 66)Chief Medical Officer Comp: $327.5kKey CompetitorsGRI BioNASDAQ:GRIAmpio PharmaceuticalsNYSE:AMPEBellicum PharmaceuticalsNASDAQ:BLCMNovaBay PharmaceuticalsNYSE:NBY180 Life SciencesNASDAQ:ATNFView All CompetitorsInsidersHoward J WeismanSold 162 sharesTotal: $166.86 ($1.03/share)Michael DerbySold 185 sharesTotal: $190.55 ($1.03/share)John F CoelhoSold 12 sharesTotal: $12.24 ($1.02/share)Michael DerbySold 539 sharesTotal: $1,740.97 ($3.23/share)Zachary RomeSold 958 sharesTotal: $2,931.48 ($3.06/share)View All Insider Transactions PXMD Stock Analysis - Frequently Asked Questions Should I buy or sell PaxMedica stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PaxMedica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PXMD shares. View PXMD analyst ratings or view top-rated stocks. What is PaxMedica's stock price target for 2024? 1 equities research analysts have issued twelve-month target prices for PaxMedica's shares. Their PXMD share price targets range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 332.3% from the stock's current price. View analysts price targets for PXMD or view top-rated stocks among Wall Street analysts. How have PXMD shares performed in 2023? PaxMedica's stock was trading at $34.51 on January 1st, 2023. Since then, PXMD shares have decreased by 98.0% and is now trading at $0.6940. View the best growth stocks for 2023 here. Are investors shorting PaxMedica? PaxMedica saw a increase in short interest in November. As of November 15th, there was short interest totaling 327,500 shares, an increase of 651.1% from the October 31st total of 43,600 shares. Based on an average daily volume of 1,730,000 shares, the days-to-cover ratio is presently 0.2 days. View PaxMedica's Short Interest. When is PaxMedica's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our PXMD earnings forecast. How were PaxMedica's earnings last quarter? PaxMedica, Inc. (NASDAQ:PXMD) posted its quarterly earnings data on Wednesday, November, 15th. The company reported ($5.20) EPS for the quarter. When did PaxMedica's stock split? PaxMedica shares reverse split on the morning of Tuesday, October 31st 2023. The 1-17 reverse split was announced on Monday, October 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did PaxMedica IPO? (PXMD) raised $9 million in an initial public offering on Friday, August 26th 2022. The company issued 1,600,000 shares at a price of $4.50-$6.50 per share. Craft Capital Management and R.F.Lafferty & Co. acted as the underwriters for the IPO. How do I buy shares of PaxMedica? Shares of PXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PXMD) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PaxMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.